

CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, October 16, 2020

In accordance with Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), is hereby reported the following:

### **INSIDE INFORMATION**

Further to communication on Inside Information dated April 28, 2020 (register number 188), the Company reports that its APLICOV-PC clinical trial with Aplidin<sup>®</sup> (plitidepsin) for the treatment of adult patients with COVID-19, who required hospitalization, has achieved both its primary safety and secondary efficacy endpoints.

Three patient cohorts, with three different plitidepsin dose levels (1.5mg - 2.0mg - 2.5mg), administered over three consecutive days, have been evaluated in the study, in patients with COVID-19 who required being admitted to hospital.

The patients' viral load was evaluated quantitatively, at the same center, at the beginning of the treatment and on days 4, 7, 15 and 30. The study has demonstrated a substantial reduction of the viral load in patients between days 4 and 7 from starting the treatment, the average reduction of the viral load on day 7 was 50% and on day 15, 70%. More than 90% of the patients included in the trial had medium or high viral loads on beginning the treatment.

80.7% of patients have been discharged on or before the 15<sup>th</sup> day of hospitalization, and 38.2% before the 8<sup>th</sup> day (according to the protocol, they must be hospitalized for a minimum of 7 days). Furthermore, a remarkable correlation has been observed between the decrease in viral load, the clinical improvement and the resolution of pneumonia, as well as a drop in inflammation parameters, such as the C-reactive protein (CRP).

By day 30, on the programmed visit to the clinic, none of the patients treated with plitidepsin had developed any signs or symptoms of COVID-19.

These results confirm both the safety, already observed in other studies with approximately 1,300 cancer patients treated at much higher doses; and the activity already seen in *in vitro* and *in vivo* studies carried out at different prestigious international laboratories.



Following the results obtained in this first group of patients and discussions with the Spanish Agency for Medicines and Healthcare Products (AEMPS), in order to keep the study open in hospitals, and to allow patient access to plitidepsin, the Company has obtained the authorization for an extension of the patient cohort. This extension will help to obtain more data on the treatment of this indication.

With these data, the Company will begin, in the next few days, conversations with the regulatory agencies to define the next phase III pivotal study for plitidepsin in patients with COVID-19, who require hospitalization.

The complete study data will be submitted to upcoming scientific conferences and/or in an article in a prestigious medical journal.

On Monday, October 19<sup>th</sup>, at 11:00 CET, a press conference will be held to inform the results, with the participation of the trial's principal researchers, which will be available online.

Please find attached press release that will be distributed to the media today.

## PharmaMar announces positive results of its APLICOV trial against COVID-19

- The study has met the primary safety endpoint.
- The trial has achieved a substantial reduction in viral load and the C-reactive protein (CRP) in patients.
- 80.7% of the patients have been discharged before the 15<sup>th</sup> day of hospitalization, and 38.2% before the 8<sup>th</sup> day (according to the protocol, they must be in hospital for a minimum of 7 days).
- PharmaMar announces that it will begin a Phase III pivotal study in the near future.

Madrid, October 16<sup>th</sup>, 2020. – PharmaMar (MSE:PHM) has announced today that its APLICOV-PC<sup>1,2</sup> clinical trial with Aplidin® (plitidepsin) for the treatment of adult patients with COVID-19, who required hospitalization, has achieved both its primary safety and secondary efficacy endpoints.

Three patient cohorts, with three different plitidepsin dose levels (1.5mg - 2.0mg - 2.5mg), administered over three consecutive days, have been evaluated in the study, in patients with COVID-19 who required being admitted to hospital.

The patients' viral load was evaluated quantitatively, at the same center, at the beginning of the treatment and on days 4, 7, 15 and 30. The study has demonstrated a substantial reduction of the viral load in patients between days 4 and 7 from starting the treatment, the average reduction of the viral load on day 7 was 50% and on day 15, 70%. More than 90% of the patients included in the trial had medium or high viral loads on beginning the treatment.

80.7% of patients have been discharged on or before the 15<sup>th</sup> day of hospitalization, and 38.2% before the 8<sup>th</sup> day (according to the protocol, they must be hospitalized for a minimum of 7 days). Furthermore, a remarkable correlation has been observed between the decrease in viral load, the clinical improvement and the resolution of

---

<sup>1</sup> Spanish Clinical Trials Registry: 2020-001993-31: [reec.aemps.es/reec/estudio/2020-001993-31](https://reec.aemps.es/reec/estudio/2020-001993-31)

<sup>2</sup> ClinicalTrials.gov: NCT04382066:

<https://clinicaltrials.gov/ct2/show/NCT04382066?term=plitidepsin&draw=2&rank=8>



pneumonia, as well as a drop in inflammation parameters, such as the C-reactive protein (CRP).

By day 30, on the programmed visit to the clinic, none of the patients treated with plitidepsin had developed any signs or symptoms of COVID-19.

These results confirm both the safety, already observed in other studies with approximately 1,300 cancer patients treated at much higher doses; and the activity already seen in *in vitro* and *in vivo* studies carried out at different prestigious international laboratories.

Following the results obtained in this first group of patients and discussions with the Spanish Agency for Medicines and Healthcare Products (AEMPS), in order to keep the study open in hospitals, and to allow patient access to plitidepsin, the Company has obtained the authorization for an extension of the patient cohort. This extension will help to obtain more data on the treatment of this indication.

With these data, the Company will begin, in the next few days, conversations with the regulatory agencies to define the next phase III pivotal study for plitidepsin in patients with COVID-19, who require hospitalization.

The complete study data will be submitted to upcoming scientific conferences and/or in an article in a prestigious medical journal.

We would like to take this opportunity to extend our sincerest gratitude to the patients, their families and caregivers, as well as the dedicated medical teams and hospital staff who participated in the clinical trial and helped plitidepsin reach this point.

On Monday, October 19<sup>th</sup>, at 11:00 CET, a press conference will be held to inform the results, with the participation of the trial's principal researchers, which will be available online.

**Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

**About PharmaMar**

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules



with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca™ (lurbinectedin, PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

**Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: +34 609493127  
Miguel Martínez-Cava – Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464  
Álvaro Mateo - Communication Manager [amateo@pharmamar.com](mailto:amateo@pharmamar.com) Mobile: +34 650726009

Phone: +34 918466000

**Capital Markets & Investor Relations:**

José Luis Moreno– Capital Markets & Investor Relations Director  
María Marín de la Plaza – Capital Markets & Investor Relations  
[investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)  
Phone: +34 914444500



Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)